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Hereditary diﬀuse gastric cancer (HDGC) is a rare, inherited cancer syndrome with at least one fourth of HDGC patients having
anautosomaldominantlyinheritedmutationofCDH1(E-Cadherin). Penetranceisrelativelyhigh(70–80%lifetimeriskforgastric
cancer). It is important for pathologists to recognize the syndrome’s phenotype in early gastric lesions:patchy intramucosalsignet
ring cells often associated with pagetoid spread. Due to the insidious nature of this lesion, surveillance is limited and currently
prophylactic gastrectomy is an option chosen by many HDGC patients. We present a case report from a multidisciplinary team of
authors with a review of the literature that includes the updated guidelines for CDH1 genetic testing.
1.The Case
An asymptomatic 36-year-old male presented for an elec-
tive, increased risk, upper endoscopy (EGD). The patient’s
remarkable history included at least ﬁve family members
diagnosed with gastric carcinoma, four known to have
occurred at an early age (Figure 1). He had a documented
mutationintheCDH1(E-Cadherin) gene(1212delC)identi-
ﬁedapproximatelyonemonthpriortothissurveillanceEGD.
The EGD was essentially normal. The stomach insuﬄated
and decompressed without diﬃculty and there was no visual
evidence of mucosal changes. EGD biopsies were read as
gastric body mucosa without diagnostic abnormality and
were negative for Helicobacter pylori, intestinal metaplasia,
dysplasia, and malignancy.
Three months later, following genetic counseling, the
patient was admitted for an exploratory laparotomy with a
prophylactic total gastrectomy with D2 lymphadenectomy
and end-to-side Roux-en-Y esophagojejunostomy and nee-
dle catheter feeding jejunostomy. The patient’s sister and
two cousins had recently undergone similar prophylactic
procedures.
Surgical exploration showed no evidence of metastatic
disease. Gross pathological examination of the stomach
revealed intact, pink mucosa with normal rugae and no
masses. The entire surgical margins, multiple (>40) gastric
sections from all anatomic zones, and the entire perigastric
adiposetissueweresubmittedforhistologicreview.Histolog-
ical examination revealed multifocal, intramucosal signet-
ring cell adenocarcinoma with focal pagetoid spread of the
signet ring cellsinpreservedfundic glands(Figure 2(a)).The
sections were negative for gastric dysplasia and Helicobacter
pylori. All margins and lymph nodes were negative for tumor
(AJCC pathologic stage pT1a pN0).
The patient had an uneventful postoperative recovery
with an upper gastrointestinal study done on postoperative
day #5 that showed no anastomotic leaks or strictures.
He was discharged on postoperative day #7. Followup
examinations revealed extensive weight loss (approximately
50lbs) but the patient was otherwise doing well.2 Pathology Research International
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Figure 1: Pedigree of case study (index) patient (shaded grey). Note that ﬁve additional family members show a history of gastric cancer
with the youngest presentation being 19 years of age. Double outline indicates positive genetic testing for E-Cadherin mutation (1212delC).
(a) (b)
Figure 2: (a) Focal intramucosal signet-ring cell adenocarcinoma in case study patient with known CDH1 mutation. Insert highlights area
of pagetoid spread. (b) Focal absence of E-Cadherin staining highlights the tumor cluster in case study patient. In those HDGC cases in
which tumor cells show decreased E-cadherin expression, the normal background epithelium serves as an excellent internal control.
2.MolecularCarcinogenesis
Only a small number, 2–8%, of all gastric carcinomas
arise from inherited gastric cancer syndromes [1, 2]. The
majority of families with autosomal dominant familial
gastric carcinoma will have the diﬀuse, poorly diﬀerentiated
(linitis plastica) morphologic subtype and are referred to
as hereditary diﬀuse gastric cancer (HDGC). A germline
mutation in the tumor suppressor gene CDH1 (E-Cadherin)
is identiﬁed in approximately 25–48% of individuals with
HDGC [3, 4]. E-Cadherin is an epithelial cell-cell adhe-
sion molecule essential to cell diﬀerentiation and normal
epithelial cell architecture. It is therefore not surprising that
germline mutations in E-Cadherin are highly speciﬁc for
familieswhomeetHDGCcriteriaandhasnotbeendescribed
in families with inherited intestinal type/morphology gastric
carcinoma [3, 5, 6].
In 1999, the International Gastric Cancer Linkage Con-
sortium(IGCLC)mettoﬁrstdeﬁnecriteriarequiredtoselect
those patients appropriate to receive mutational screening
for HDGC [5]. Strict application of these 1999 IGCLC
criteria found approximately one third of screened patients
to be heterozygous for a germline, point or frameshift,
mutation of the CDH1 gene on chromosome 16q22.1 [6,
7]. This implies that there are either currently uniden-
tiﬁable CDH1 mutations or other genes causing HDGC
in some families. Medical management recommendations
are particularly diﬃcult in these families with undetectable
CDH1 mutations. There are at least twenty-seven docu-
mented inactivating (truncating) CDH1 mutations scattered
at various exons along the E-Cadherin gene described in
a diverse ethnic population [3, 8–10]. In a recent study
addressing patients that met HDGC criteria but lacked
CDH1 germline point mutations, Oliveira et al. found that
6.5% of their study patients had large deletions aﬀecting
the CDH1 locus by using multiplex ligation-dependent
probeampliﬁcation(MLPA)[7].Therefore, analysisforlargePathology Research International 3
Table 1: (Updated) Criteria for CDH1 molecular genetic testing.
Two or more cases ofgastric cancer in a family, withat leastone histologicallyconﬁrmed diﬀuse gastric cancer (DGC)
diagnosed before the age of 50.
Three or more conﬁrmed cases of DGC in 1st or 2nd degree relatives, independent of age of onset.
An individual diagnosed with DGC before the age of 40.
An individual or family members diagnosed with DGC and lobular breast cancer, one being diagnosed before the age
of 50.
genomicdeletionsusingalternativetechniquessuchasMLPA
or array comparative genomic hybridization (CGH) should
be explored in highly suspicious cases in which standard
DNA sequencing is negative for point mutations.
The current hypothesis for how HDGC susceptibility
cancers lose their CDH1 heterozygosity and thus their E-
Cadherin expression follows the “two-hit” mutation theory
[11]. Hypermethylation of the CDH1 promoter is the most
common cause of inactivation of the second allele; however,
mutation and loss of heterozygosity (LOH) are also well-
documented culprits [11–13]. Interestingly, the mechanisms
of the “2nd hit” may diﬀer in primary tumors versus
metastases, an important consideration for therapeutics.
The morphologic expression of the second hit is multifocal
clusters of tumor cells that have lost or show abnormal
(reduced) E-cadherin expression (Figure 2(b)). The sub-
sequent step, progression to invasion of the submucosa,
is less well deﬁned. The current line of thought involves
an integrated role between additional genetic events and
changes in microenvironment. Unfortunately, there are no
current means of predicting the time course between tumor
expansion and submucosal invasion.
The CDH1 mutation carries a high penetrance with
carriers of germline mutations having an estimated lifetime
risk of 67% in men and 83% in women to develop gastric
carcinoma [4, 14]. In HDGC families, the most commonly
described malignancy other than diﬀuse gastric carcinoma is
lobularbreastadenocarcinoma.Femalecarriersofagermline
CDH1 mutation have a 40% lifetime risk of developing this
subset of breast cancer[14]. In general, susceptibility cancers
in HDGC occur at a relatively early age, with the average age
of presentation of diﬀuse gastric carcinoma being 38 years
[15].
3.ClinicopathologicManagement
The IGCLC guidelines were ﬁrst developed in 1999 to sup-
port clinical management of families felt to be predisposed
to gastric carcinoma [5]. This multidisciplinary group has
recently provided us with an updated, somewhat broadened
version of their original guidelines as to which patients
shouldbeoﬀeredmoleculargenetictesting(Table 1)[4].Any
patient who meets the minimum requirements for HDGC
listed in Table 1 should be oﬀered genetic counseling and
testing for the CDH1 mutation. Health care professionals
experienced in cancer genetics must provide those patients
that choose to undergo this testing pre- and posttesting
genetic counseling.
In general, annual endoscopy using a white light high-
deﬁnition endoscope is recommended for surveillance of
HDGC patients. Using histopathology mapping in six
gastrectomy specimens from New Zealand Maori HDGC
families, Charlton et al. showed a preferential pattern of
intramucosal diﬀuse gastric carcinoma in the body-antral
transitional zone [16]. Based on their study, they proposed
a targeted approach to endoscopy with the goal of mini-
mizing sampling error. However, results from prophylactic
gastrectomy specimens from other areas of the world did
not show similar ﬁndings [17–21]. Due to the discrepancy
in study results regarding localization of early gastric lesions,
multiple gastric biopsies representing all of the major gastric
anatomic zones is recommended. The HDGC endoscopic
protocol provided by the most recent consensus guidelines
suggests the following biopsies: a single antral biopsy taken
ﬁrst for surveillance of H. pylori s t a t u s ,a n yf o c a ll e s i o n s ,a n d
in addition at least three biopsies from each anatomical area
(prepyloric area, gastric antrum, transitional zone, gastric
body, gastric fundus, and gastric cardia) [4]. This extensive
sampling is driven by the insidious phenotype of this disease
(patchy, diﬀuse growth pattern of gastric carcinoma under
endoscopically normal gastric mucosa), which leads to low
sensitivity in currently available surveillance procedures.
Our HDGC patient was found to have occult intra-
mucosalsignetringcelladenocarcinomaonresectiondespite
having a normal endoscopic appearance to the stomach and
nodiagnosticﬁndingsbyrandomendoscopicbiopsies.Upon
review of the literature representing diﬀerent, independent
HDGC families, the identiﬁcation of indolent gastric cancer
is consistent with the pathology found in the majority of
casesfollowing prophylacticgastrectomy [19,20,22].Inlight
of the inherent limitations to the current screening proce-
dures/tests available for HDGC patients, a prophylactic gas-
trectomy is not onlya reasonable optionbutsome may argue
a life saving one. The estimated 30-day postgastrectomy
mortality rate is cited as 3–6% [23]a n dm o s tl i k e l yr e a c h e s
even smaller numbers when a gastrointestinal surgeon who
routinely performs gastrectomies and other major surgeries
performs theprocedure.Toputthisinperspective,the5-year
mortality rate in patients with symptomatic, invasive gastric
carcinoma is 90% [24].
However, this procedure is not without long-term
complications. All patients who undergo gastrectomy will
have postoperative weight loss. Many will have metabolic
complications including malabsorption, diarrhea, and/or
“dumping syndrome.” Dieticians are often required to assist
postsurgical patients in nutritional management. There are4 Pathology Research International
also secondary surgical complications such as esophageal
strictures. A more thorough understanding of the long-term
physical and psychological eﬀects of this surgery will only
emerge through followup of these relatively young HDGC
patients. The current consensus guidelines have called for
a central registry of HDGC patients who have undergone
prophylactic gastrectomies [4]. This would provide essential
prospective data regarding eﬀects of the surgery as well as
long-term followup regarding disease-free status.
Prophylactic gastrectomies for HDGC will most likely
occur at major academic institutions in which special-
ized gastrointestinal pathologist are readily available. The
gastric specimen is inked and ﬁxed with lymph node
retrieval asin any gastrectomy specimen. However,following
adequate (overnight) ﬁxation, these specimens should be
photographed with mapped sampling occurring from all
anatomical zones as well as submission of the entire surgical
margins. If carcinoma is not identiﬁed, additional mapped
sampling will be required. The focal intramucosal signet
ring cells are generally identiﬁed on H & E morphology.
A combination of cytokeratin (positive immunoreactivity)
and E-Cadherin (negative or reduced immunoreactivity;
see Figure 2(b)) can highlight these foci, especially in areas
of pagetoid spread. Interestingly, in their study of eight
total gastrectomy specimens done for germline E-cadherin
mutations, Rogers et al. found two cases which showed
reversion of E-cadherin expression in foci of deeply invasive
adenocarcinoma while the superﬁcial signet ring cells cancer
showed the expected loss or reduced E-cadherin expression
[21]. Additional, nonspeciﬁc histologic features described
in some cases of HDGC include foveolar hyperplasia with
or without tufting, cytoplasmic vacuolization, and clustered
histiocytes or vaguely granulomatous reactions occurring
around ruptured glands [4, 18, 21].
The IGCLC also suggests that female carriers of the
CDH1 mutation receive high-risk screening for lobular
breast adenocarcinoma from the age of 35. Other cancers,
such, signet ring cell carcinoma of the colon, have been
proposed to be associated with HDGC. Colon cancer screen-
ing may therefore be recommended in HDGC patients who
have a pedigree showing colon carcinoma presenting before
the age of 40. This type of personalized heightened cancer
screening emphasizes the need for thorough documentation




At least one third of all patients with HDGC have an
autosomal dominantly inherited mutation of the CDH1 (E-
Cadherin) gene. Penetrance is high with a speciﬁc phenotype
of diﬀuse, signet ring cell morphology. Pathologists should
beaware ofthis phenotypeofpatchy clustersofintramucosal
signet ring tumor cells associated with a pagetoid spread of
individualsignetring cells(Figure 2),althoughnotknown to
beentirelyspeciﬁc, thisﬁnding, especially ina youngpatient,
may warrant a discussion with the treating clinician regard-
ing referral to a genetic counselor. In patients known to
have HDGC,a multidisciplinary approach, includinggenetic
counselors, subspecialized pathologists, clinical researchers,
dietitians, and experienced gastrointestinal surgeons, is
essential in the management of these patients. Due to the
insidious nature of early lesions in this disorder, endoscopy
is not an adequate screening method. However, annual
white light high-deﬁnition endoscopy with extensive biopsy
sampling may provide a method of surveillance for those
patients who are not good surgical candidates, who refuse
more aggressive methods, or are carriers of mutations (e.g.,
missense) where clinical signiﬁcance is less deﬁned.
The prophylactic gastrectomy specimen of our patient
known to carry a CDH1 mutation was found to have
multifocal intramucosal signet ring cell adenocarcinoma
despite normal endoscopic exam and biopsies. Previous
publications, of at least three major groups, document the
same ﬁnding in multiple HDGC families, making these risk-
reducing gastrectomies simultaneously therapeutic. Cur-
rently there is no way of determining the latent period
between the intramucosal CDH1 −/− adenocarcinoma and
invasion into submucosa. However, it is important to note
that our patient had at least two family members that died
of HDGC at ages younger (19 and 35 years of age) than
his age at the time of gastrectomy (36 years of age). Until
better screening tests emerge, gastrectomy may be the only
adequate means of lengthening survival in carriers of the
CDH1 mutation.
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